DNDI-6510
DNDI-6510 (Compound (S) -x38) is a non-covalent SARS-CoV-2 MPro inhibitor with a IC50 of 0.04 μM. DNDI-6510 has a potent antiviral activity across SARS-CoV-2 and its variants as well as a weak efficacy to SARS-CoV-1. DNDI-6510 significantly improves drug exposure in metabolically humanized mice model (8HUM) [1].
Product Specifications
UNSPSC
12352005
Target
Cytochrome P450; SARS-CoV; Virus Protease
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Field of Research
Infection
Smiles
CNC(C1(CC1)N2C[C@@]3(C4=C(C2=O)C=CC(Cl)=C4)CCN(C3=O)C5=C6C=CC=CC6=CN=C5)=O
Molecular Formula
C26H23ClN4O3
Molecular Weight
474.94
References & Citations
[1]Griffen E J, et al. Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor[J]. bioRxiv, 2025: 2025.06. 16.660018.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CYP2; CYP3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
